Inclusion body myositis topical collection on nerve and muscle

Current Neurology and Neuroscience Reports

Volumn 13, Issue 1, 2013, Pages

  Dimachkie, Mazen M ^a   Barohn, Richard J ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Idiopathic inflammatory myopathies; Inclusion body myositis; Pathology; Pathophysiology; Polymyositis; Prognosis; Treatment

Indexed keywords

ALEMTUZUMAB; ARIMOCLOMOL; BETA INTERFERON; CORTICOSTEROID; ETANERCEPT; FOLLISTATIN; LITHIUM CHLORIDE; METHOTREXATE; OXANDROLONE; PLACEBO; SIMVASTATIN; THYMOCYTE ANTIBODY; ANTIINFLAMMATORY AGENT; CREATINE KINASE;

ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; HISTOPATHOLOGY; HUMAN; INCLUSION BODY MYOSITIS; KINESIOTHERAPY; LABORATORY TEST; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRAL GENE THERAPY; BLOOD; DIAGNOSTIC IMAGING; FEMALE; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOTHERAPY; REVIEW; SKELETAL MUSCLE;

ANTI-INFLAMMATORY AGENTS; CREATINE KINASE; DIAGNOSTIC IMAGING; ELECTROMYOGRAPHY; FEMALE; HUMANS; MALE; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; PHYSICAL THERAPY MODALITIES;

EID: 84873096100     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0321-4     Document Type: Article

References (53)

1. Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve. 2000;23(6):970-2. (Pubitemid 30354508)
2. Lotz BP, Engel AG, Nishino H, Stevens JC, Litch WJ. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112(Pt 3):727-47. (Pubitemid 19151167)
3. Badrising UA, Maat-Schieman ML, van Houwelingen JC, et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. Neurology. 2005;252(12):1448-54. (Pubitemid 41803832)
4. Wilson FC, Ytterberg SR, St Sauver JL, et al. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol. 2008;35(3):445-7. (Pubitemid 351374418)
5. Amato AA, Gronseth GS, Jackson, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1995;40:581-6.
6. Barohn RJ, Amato AA. Inclusion body myositis. Curr Treat Options Neurol. 2000;2:7-12.
7. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in The Netherlands: a nationwide study. Neurology. 2000;55:1385-7.
8. Lindberg C, Persson LI, Bjorkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological, and laboratory findings in 18 cases. Acta Neurol Scand. 1994;89:123-31. (Pubitemid 24095268)
9. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol. 1992;19:1385-9.
10. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability, and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry. 2008;79(9):1056-60.
11. Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology. 1995;45(7):1302-4.
12. Estephan B, Barohn RJ, Dimachkie MM, et al. Sporadic IBM: a case cohort. J Clin Neuromuscul Dis. 2011;12(3):18-9.
13. •• Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38(5):705-13. Authors of this article propose diagnostic criteria for definite and possible sporadic inclusion body myositis based on a combination of clinical features and laboratory findings including serum creatine kinase, electromyography, and muscle histopathology. This is the first major effort to define diagnostic criteria for IBM. These criteria have withstood the test of time with some additions as in reference 14.
14. •• Hilton-Jones D, Miller A, Parton M, et al. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June, 2008. Neuromuscul Disord. 2010;20(2):142-7. In addition to the Griggs categories of pathologically defined IBM and possible IBM, participants of the 2008 European Neuromuscular Center workshop introduced clinically defined IBM to include IBM cases with weakness involving finger flexion more than shoulder abduction as well as knee extension more than hip flexion. The pathologic criteria for possible IBM and clinically defined IBM are invasion of non-necrotic fibers by mononuclear cells, or rimmed vacuoles, or increased MHC-1 expression on the surface of muscle fibers. This facilitates the diagnosis of patients who fulfill clinical criteria for IBM but do not have the pathologic features set forth by Griggs et al.
15. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry. 2009;80(11):1186-93.
16. Garlepp MJ, Laing B, Zilko PJ, et al. HLA associations with inclusion body myositis. Clin Exp Immunol. 1994;98:40-5. (Pubitemid 24315449)
17. Degardin A, Morillon D, Lacour A, Cotten A, Vermersch P, Stojkovic T. Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skeletal Radiol. 2010;39(12):1219-27.
18. Cox FM, Reijnierse M, van Rijswijk CS, Wintzen AR, Verschuuren JJ, Badrising UA. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology. 2011;50(6):1153-61.
19. Maetzler W, Reimold M, Schittenhelm J, et al. Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition. J Neurol Neurosurg Psychiatry. 2011;82(9):1060-2.
20. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008;70(6):418-24.
21. Van der Meulen MF, Hoogendijk JE, Moons KG, Veldman H, Badrising UA, Wokke JH. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord. 2001;11:447-51. (Pubitemid 32510004)
22. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve. 2007;35(1):17-23. (Pubitemid 46052644)
23. Greenberg SA. Inclusion body myositis. Curr Opin Rheumatol. 2011;23(6):574-8.
24. Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology. 2002;59(8):1170-82. (Pubitemid 35192386)
25. Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology. 2005;65(11):1782-7.
26. • Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 kDa muscle protein in inclusion body myositis. PLoS One. 2011;6:e20266. Since microarray studies reported abundant immunoglobulin gene transcripts in IBM muscle derived from local abundant plasma cells, this provided a rationale for searching for circulating autoantibodies. Imunoblots against normal human muscle demonstrate that 52 % of IBM patient samples recognized a 43 kDa muscle protein. None of those with other diseases or healthy volunteers had this protein.
27. Askanas V, Engel WK. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology. 2006;66(2 Suppl 1):S39-48.
28. Wojcik S, Engel WK, McFerrin J, Paciello O, Askanas V. AbetaPP-overexpression and proteasome inhibition increase alpha B-crystallin in cultured human muscle: relevance to inclusion-body myositis. Neuromuscul Disord. 2006;16(12):839-44. (Pubitemid 44855597)
29. Askanas V, Engel WK. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med. 2011;40(4 Pt 2):e219-35.
30. Salajegheh M, Pinkus JL, Nazareno R, et al. Nature of "Tau" immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve. 2009;40(4):520-8.
31. • Nogalska A, D'Agostino C, Engel WK, Klein WL, Askanas V. Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol. 2010;120(5):661-6. Askanas' group reported for the first time in 2010 that IBM muscle samples had accumulation of toxic low-molecular weight amyloid β oligomers on dot-immunoblots with a variety of molecular weights and intensity but none of the control muscle biopsies had amyloid β oligomers. Nonfibrillar cytotoxic "Aβ-Derived Diffusible Ligands" originally derived from Aβ42 are prominently increased on dot-immunoblots, being consistent with the concept that intracellular toxicity of Ab42 oligomers is likely an important aspect of IBM pathogenesis. Finally, they demonstrated in cultured human muscle fibers that inhibition of autophagy is a novel cause of Aβ oligomerization.
32. Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve. 2009;40:19-31.
33. Verma A, Bradley WG, Ringel SP. Treatment-responsive polymyositis transforming into inclusion body myositis. Neurology. 2008;P060.19.
34. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11):3176-84.
35. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology. 1994;44(8):1516-8. (Pubitemid 24247450)
36. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712-6. (Pubitemid 27120112)
37. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56:323-7. (Pubitemid 32144142)
38. Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology. 2001;57:1566-70.
39. Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology. 2004;63:718-20.
40. Badrising UA, Maat-Schieman ML, Ferrari, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol. 2002;51:369-72. (Pubitemid 34206293)
41. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology. 2003;61:260-2. (Pubitemid 36875317)
42. Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felic KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology. 2002;58(7):1081-7. (Pubitemid 34298550)
43. Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology. 2006;66(2 Suppl 1):S123-4.
44. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(Pt 6):1536-44.
45. Sancricca C, Mora M, Ricci E, Tonali PA, Mantegazza R, Mirabella M. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci. 2011;32(5):841-7.
46. Saperstein DS, Levine T, Hank N, Kitazawa M, Bowser R, LaFerla F. Pilot Trial of lithium treatment in inclusion body myositis. Neurology. 2011;76 Suppl 4:A106.
47. Pasquali L, Longone P, Isidoro C, Ruggieri S, Paparelli A, Fornai F. Autophagy, lithium, and amyotrophic lateral sclerosis. Muscle Nerve. 2009;40(2):173-94.
48. Wang Y, He J, McVey AL, et al. Twelve-month change of IBMFRS in the arimocolomol inclusion body myositis pilot study. Poster 7.255 presented at the American Academy of Neurology. Annual Meeting. New Orleans, LA, USA; April 26 2012. Actual page etc from Dr. Baroh's CV).
49. Sekul EA, Dalakas MC. Inclusion body myositis: new concepts. Semin Neurol. 1993;13(3):256-63. (Pubitemid 23300092)
50. Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134(Pt 11):3167-75.
51. Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology, and inflammatory reaction. J Rehabil Med. 2003;35(1):31-5. (Pubitemid 36204070)
52. Johnson GL, et al. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2007;8:187-94. (Pubitemid 47052000)
53. Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009;10(4):178-84.